4/A: Ionis Pharmaceuticals EVP Corrects Stock Sale Reporting in Amended SEC Filing

Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals, amends a previous SEC Form 4 filing to correct the number of shares sold on February 2, 2024.

Summary

• Patrick R. O'Neil, an executive at Ionis Pharmaceuticals, filed an amended Form 4 with the SEC.
• The amendment corrects the number of shares sold on February 2, 2024, which was originally reported as 1,961 restricted stock units but has been revised to reflect the actual amount of shares sold.
• The corrected filing indicates that 1,995 shares of common stock were sold at a weighted average price of $49.6738.
• Following the transaction, O'Neil beneficially owns 48,627 shares of Ionis Pharmaceuticals.
• The shares were sold in multiple transactions at prices ranging from $49.60 to $49.80.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing correcting a previous error. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Industry Context

This filing is a routine disclosure related to insider trading activities, which are common in publicly traded companies. Investors monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders are informed about the corrected stock sale transaction by a company executive.
• The correction ensures transparency and accurate reporting of insider trading activities.

Key Dates